INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 46h ago
House PTR6h ago
SEC 13F6h ago
Robinhood Chain6h ago

Most active filers · 30d

  1. 01FWFogarty Patrick W0B / 206S206 trades$1.10M
  2. 02Kurtz George0B / 202S202 trades$48.06M
  3. 03SPSaba Capital Management, L.P.67B / 19S · 11 late86 trades$21.51M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09SISarowitz Steven I2B / 34S36 trades$21.18M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. BUYMTDRMatador Resources CoNov 5 – Nov 189 insiders$1.02M
  3. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  4. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  5. SELLMGNIMAGNITE, INC.Nov 5 – Nov 178 insiders$2.77M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

73,431 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
MK
McCarthy Brian K.Pres.,Global Sales & Field Ops
RBRKRubrik, Inc.
Open-market sale · 10b5-1 plan
SELL$140K
2,000 sh
Jan 12, 2026Jan 13, 2026
Page 1516 of 1836
← PrevNext →
traded Jan 12, 2026
+1d
SEC Form 4

Evidence

11
FM
Francis John Milton IVChief Operating Officer
ROLRHigh Roller Technologies, Inc.
Grant or award
A—
75.0K sh
Jan 8, 2026Jan 13, 2026
traded Jan 8, 2026
+5dSEC Form 4

Evidence

11
BS
Baig SaqibChief Accounting Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$35K
5,000 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TC
Thygesen Allan C.Director, President and CEO
DOCUDOCUSIGN, INC.
Open-market sale · 10b5-1 plan
SELL$21K
300 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$43K
80 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
LH
Litinsky James H.Director, Chairman and CEO
MPMP Materials Corp. / DE
Grant or award
A—
65.4K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$16K
30 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$48K
89 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$21K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$43K
80 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

10
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
VL
Vorakoun LisaSVP & CHIEF ACCOUNTING OFFICER
CTOCTO Realty Growth, Inc.
Tax withholding
F$30K
1,635 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

9
BK
Blasing KarenDirector
ZSZscaler, Inc.
Grant or award
A—
1,076 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

9
FC
Follmann ChristianChief Operating Officer
HTGCHercules Capital, Inc.
Tax withholding
F$22K
1,178 sh
Jan 11, 2026Jan 13, 2026
traded Jan 11, 2026
+2dSEC Form 4

Evidence

9
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$2,760
1,401 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$5,875
2,982 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
FA
Fasano Gerard ADirector
VVXV2X, Inc.
Grant or award
A—
838 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
HA
Hanson Eric ACFO
LWAYLifeway Foods, Inc.
Tax withholding
F$39K
1,720 sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

9
DJ
Dolan John JosephChief Financial Officer
EHTHeHealth, Inc.
Tax withholding
F$2,156
539 sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

9
GG
Galimi Gavin G.SVP, General Counsel & Secr.
EHTHeHealth, Inc.
Tax withholding
F$3,864
966 sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

9
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
BZ
Botelho Kiersten ZazaChief Legal Officer & CCO
HTGCHercules Capital, Inc.
Tax withholding
F$15K
822 sh
Jan 11, 2026Jan 13, 2026
traded Jan 11, 2026
+2dSEC Form 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$6,345
3,221 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
DD
Doogan DeclanDirector
TENXTENAX THERAPEUTICS, INC.
Grant or award
A—
30.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
HA
Hanson Eric ACFO
LWAYLifeway Foods, Inc.
Option exercise
M—
2,488 sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

9
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$387K
24.5K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
HR
Hunter RobynDirector
TENXTENAX THERAPEUTICS, INC.
Grant or award
A—
30.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
CE
Choi EmiliePresident & COO
COINCoinbase Global, Inc.
Grant or award
A—
160.8K sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

9
FJ
Fazio JuliePresident of Subsidiary
UGIUGI CORP /PA/
Option exercise
M—
1,350 sh
Jan 11, 2026Jan 13, 2026
traded Jan 11, 2026
+2dSEC Form 4

Evidence

9
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
WA
Wagner Paul A.Director, SEE REMARKS
FBRXForte Biosciences, Inc.
Grant or award
A—
180.0K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

9
FJ
Fazio JuliePresident of Subsidiary
UGIUGI CORP /PA/
Tax withholding
F$30K
805 sh
Jan 11, 2026Jan 13, 2026
traded Jan 11, 2026
+2dSEC Form 4

Evidence

9
VM
VanHimbergen Robert MEVP and CFO
ELANElanco Animal Health Inc
Grant or award
A$190
8 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
BK
Buck Kristen KEVP, R&D and CMO
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$5,875
2,982 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Tax withholding
F$1,539
781 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

9
SD
Semler DakotaDirector, Chief Executive Officer
XOSXos, Inc.
Tax withholding
F$12K
5,620 sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

9
BM
Barbeau Michelle MarieChief Revenue Officer
EHTHeHealth, Inc.
Tax withholding
F$1,516
379 sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence